Competition opens to elevate early-stage medtech pitches

Medtech entrepreneurs are being invited to the Early-Stage Innovation Forum (ESIF), a unique platform for developers to pitch their innovation at the 2024 AusMedtech national conference in Adelaide.

The ESIF rapid-fire pitch competition provides presenters with an opportunity to pitch their early-stage innovation to a panel of expert judges for feedback that will prepare them for their capital raising journey ahead.

This exclusive opportunity offers early-stage projects and technologies in the areas of medical devices and diagnostics, digital health and enabling technologies, the chance to gather feedback essential for commercialising, from a panel of industry experts as well as corporate VCs and early-stage investors.

During their seven-minute presentation, presenters will be required to outline the problem they are trying to address, their innovative approach to solving the problem, the technology’s competitive advantage, development plan and investment proposal.

Companies that have advanced beyond seed funding are encouraged to express their interest in AusMedtechInvest 2024, Australia’s inaugural boutique medtech investment roundtable forum, and aims to build meaningful personal connections between innovative medical technology (devices and diagnostic) businesses and investors, and help great ideas attract the capital needed to thrive in a fast-paced, competitive market. Investors are also invited to apply for their complementary pass here.

The ESIF is run bi-annually and features presentations from Australia’s local research institutes, universities, hospitals, and pre-series A companies.

QIMR Berghofer’s A/Prof Michelle Hill, winner of Best Translational Research at the AusMedtech 2023 ESIF, said: “The feedback from the panel will help to further refine the pitch as I will be looking for investors for my startup to commercialise the discovered biomarkers to new blood tests for ovarian cancer diagnosis and early detection.”

/Public Release. View in full here.